CoChat
Sign Up
Cited by 62Chronic Kidney Disease and DiabetesDialysis and Renal Disease ManagementAcute Kidney Injury Research

Circulating Serum Trefoil Factor 3 (TFF3) Is Dramatically Increased in Chronic Kidney Disease

Open access
Du, Ting-yi, Luo, Hui-ming, Qin, Hai-chun, Wang, Fang, Wang, Qing, Xiang, Yang, Zhang, Yun·2013·PLoS ONE
DOI 10.1371/journal.pone.0080271PMC PMC3840008
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVES: Trefoil factor 3 (TFF3) is a small peptide that plays an important role in mucosal protection, cell proliferation, and cell migration. The aberrant expression of TFF3 is correlated with gastrointestinal inflammation, solid tumors, and other clinical diseases. The objective of this study was to identify the distribution characteristics of serum TFF3 in common clinical diseases. MATERIALS AND METHODS: A large prospective randomized study of 1,072 Chinese patients was performed using an enzyme-linked immunosorbent assay (ELISA) to examine the serum TFF3 concentrations in patients with different diseases. A matched case-control study was conducted on patients with chronic kidney disease (CKD) stages 1-5. Immunohistochemistry (IHC) was performed using renal tissues to determine the relationship between the severity of CKD and the serum and urine concentrations of TFF3 peptides. RESULTS: The mean serum concentrations of TFF3 in patients with CKD, metastatic and secondary carcinoma (MC) and acute gastroenteritis (AG) (200.9 ng/ml, 95.7 ng/ml and 71.7 ng/ml, respectively) were significantly higher than those in patients with other common clinical diseases. A positive correlation tendency was observed between the serum TFF3 concentrations and the severity of CKD. The mean serum TFF3 values for CKD stages 1-5 were 23.6 ng/ml, 29.9 ng/ml, 54.9 ng/ml, 85.0 ng/ml and 176.6 ng/ml, respectively. The same trend was observed in the urine TFF3 concentrations and the CKD stages. The creatinine(Cr)-corrected concentrations of TFF3 in urine were 367.1 ng/mg·Cr, 910.6 ng/mg·Cr, 1,149.0 ng/mg·Cr, 1,610.0 ng/mg·Cr and 3,475.0 ng/mg·Cr for CKD stages 1-5, respectively. IHC revealed that TFF3 expression was concentrated in tubular epithelial cells. CONCLUSIONS: The influence of kidney injuries must be fully considered when performing clinical TFF3 research. Further studies on TFF3 in CKD will contribute to our understanding of its pathological roles and mechanisms in other diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0080271

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CST3, B2M, and TFF3 have all been used to monitor kidney function, as their plasma levels increase upon kidney injury.

    “have all been used to monitor kidney function, as their plasma levels increase upon kidney injury71”

    From Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) · cites this paper as [71]

    The Discussion reports that serum TFF3 is higher in patients with chronic kidney disease and rises with CKD severity. It does not establish that TFF3 has been used to monitor kidney function; it describes clinical diagnostic development as a future possibility. The passages also provide no support for the claims about CST3 or B2M. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]Wong WM, Poulsom R, Wright NA (1999) Trefoil peptides. Gut 44: 890– 895. 10323896 PMC1727551
  2. [2]Taupin D, Podolsky DK (2003) Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4: 721– 732. 14506475
  3. [3]Zhang Y, Yu G, Wang Y, Xiang Y, Gao Q, et al (2011) Activation of protease-activated receptor (PAR) 1 by frog trefoil factor (TFF) 2 and PAR4 by human TFF2. Cell Mol Life Sci 68: 3771– 3780. 21461878 PMC11115081
  4. [4]Kjellev S (2009) The trefoil factor family - small peptides with multiple functionalities. Cell Mol Life Sci 66: 1350– 1369. 19099184 PMC11131466
  5. [5]Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE (2008) Are trefoil factors oncogenic? Trends Endocrinol Metab 19: 74– 81. 18054496
  6. [6]Vestergaard EM, Poulsen SS, Gronbaek H, Larsen R, Nielsen AM, et al (2002) Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 48: 1689– 1695. 12324485
  7. [7]Ciacci C, Di Vizio D, Seth R, Insabato G, Mazzacca G, et al (2002) Selective reduction of intestinal trefoil factor in untreated coeliac disease. Clin Exp Immunol 130: 526– 531. 12452845 PMC1906543
  8. [8]Yamachika T, Werther JL, Bodian C, Babyatsky M, Tatematsu M, et al (2002) Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res 8: 1092– 1099. 12006524
  9. [9]Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, et al (2005) Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res 11: 6472– 6478. 16166422
  10. [10]Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, et al (2002) Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 8: 1871– 1877. 12060630
  11. [11]Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ (2003) Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 88: 1091– 1094. 12671691 PMC2376386
  12. [12]Khoury T, Chadha K, Javle M, Donohue K, Levea C, et al (2005) Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer 35: 171– 177. 16110118
  13. [13]Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, et al (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6: e1000046. 19360088 PMC2661257
  14. [14]Vestergaard EM, Borre M, Poulsen SS, Nexo E, Torring N (2006) Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 12: 807– 812. 16467092
  15. [15]Xue H, Lu B, Zhang J, Wu M, Huang Q, et al (2010) Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 9: 545– 555. 19924834
  16. [16]Weigelt B, Verduijn P, Bosma AJ, Rutgers EJ, Peterse HL, et al (2004) Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br J Cancer 90: 1531– 1537. 15083181 PMC2409726
  17. [17]Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, et al (2008) Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer 99: 768– 773. 18682706 PMC2528153
  18. [18]Takano T, Yamada H (2009) Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma. Endocr J 56: 9– 16. 18506086
  19. [19]Levey AS, Coresh J, Balk E, Kausz AT, Levin A, et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137– 147. 12859163
  20. [20]Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, et al (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17: 2937– 2944. 16988059
  21. [21]Korbet SM (2002) Percutaneous renal biopsy. Semin Nephrol 22: 254– 267. 12012311
  22. [22]Whittier WL, Korbet SM (2004) Renal biopsy: update. Curr Opin Nephrol Hypertens 13: 661– 665. 15483458
  23. [23]Meng JR, Tang HZ, Zhou KZ, Shen WH, Guo HY (2012) TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med. doi: 10.1007/s10238-012-0210-9 22996285 · DOI
  24. [24]Zhang Y, Yu G, Jiang P, Xiang Y, Li W, et al (2011) Decreased expression of protease-activated receptor 4 in human gastric cancer. Int J Biochem Cell Biol 43: 1277– 1283. 21635966
  25. [25]Thim L, May FE (2005) Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci 62: 2956– 2973. 16374584 PMC11139098
  26. [26]Jorgensen KH, Thim L, Jacobsen HE (1982) Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas. Regul Pept 3: 207– 219. 6896240
  27. [27]Suemori S, Lynch-Devaney K, Podolsky DK (1991) Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci U S A 88: 11017– 11021. 1763017 PMC53064
  28. [28]Wright NA, Hoffmann W, Otto WR, Rio MC, Thim L (1997) Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett 408: 121– 123. 9187350
  29. [30]Hammond ME, Taube SE (2002) Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol 29: 213– 221. 12063674
  30. [31]Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E (2006) Cancer biomarkers: a systems approach. Nat Biotechnol 24: 905– 908. 16900126
  31. [32]Kalinina J, Peng J, Ritchie JC, Van Meir EG (2011) Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 13: 926– 942. 21852429 PMC3158015
  32. [33]Samson MH, Nexo E (2011) Validation of commercial assays for measurements of trefoil factor family peptides in serum. Clin Chem Lab Med 49: 2057– 2060. 21923477
  33. [34]Samson MH, Vestergaard EM, Milman N, Poulsen SS, Nexo E (2008) Circulating serum trefoil factors increase dramatically during pregnancy. Scand J Clin Lab Invest 68: 369– 374. 19172695
  34. [35]Rinnert M, Hinz M, Buhtz P, Reiher F, Lessel W, et al (2010) Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine. Cell Tissue Res 339: 639– 647. 20063012
  35. [36]Chutipongtanate S, Nakagawa Y, Sritippayawan S, Pittayamateekul J, Parichatikanond P, et al (2005) Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor. J Clin Invest 115: 3613– 3622. 16308573 PMC1288833
  36. [37]Yu Y, Jin H, Holder D, Ozer JS, Villarreal S, et al (2010) Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 28: 470– 477. 20458317
  37. [38]Astor BC, Kottgen A, Hwang SJ, Bhavsar N, Fox CS, et al (2011) Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol 34: 291– 297. 21829008 PMC3169359
  38. [39]Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, et al (2003) Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 17: 7– 16. 12522107
  39. [40]Rastaldi MP, Ferrario F, Giardino L, Dell'Antonio G, Grillo C, et al (2002) Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 62: 137– 146. 12081572
  40. [41]Zeisberg M, Kalluri R (2004) The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) 82: 175– 181. 14752606
  41. [42]Strutz F, Muller GA (2006) Renal fibrosis and the origin of the renal fibroblast. Nephrol Dial Transplant 21: 3368– 3370. 16887850
  42. [43]Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740– 746. 14644200
  43. [45]Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67: 10123– 10128. 17974953
  44. [46]Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818– 829. 18539112
  45. [47]Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, et al (2010) Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85– 97. 20008127 PMC2797872

Cited by

Sorted by citations

Authors
Du, T.-Y., Luo, H.-M., Qin, H.-C., Wang, F., Wang, Q., Xiang, Y., & Zhang, Y.
Affiliations
  • First People's Hospital of Yunnan Province (CN)
  • Kunming Institute of Zoology (CN)
Corresponding author
Zhang, Yun
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-11-25
Volume
8
Issue
11
Pages
e80271
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0080271
PMC
PMC3840008
OpenAlex
W2053943923
Cited by
62
References
2
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 9 · 2017: 6 · 2016: 4 · 2015: 5
FWCI
2.27
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Natural Science Foundation of China (973 Program, 31270835, U1132601)
  • Chinese Academy of Sciences
  • National Key Research and Development Program of China (973 Program, 2010CB529800, 2010CB529800)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
TFF3, chronic kidney disease, serum biomarkers, CKD severity, tubular epithelial cells, acute gastroenteritis, kidney injury
MeSH terms
Trefoil Factor-3, Carcinoma, Enzyme-Linked Immunosorbent Assay, Humans, Immunohistochemistry, Kidney Tubules, Neoplasm Metastasis, Peptides, Case-Control Studies, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review